MGMT Gene clinical trials
20 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
- CARv3-TEAM-E T Cells in Glioblastoma
- D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
- G-CSF After Chemo-radiation in Patients With Glioblastoma
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- Lerapolturev (PVSRIPO) in GBM
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
- WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
- A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
- Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
- Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
- CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
- A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “MGMT Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.